Insulin sensitivity / metabolic health
Lee 2015 (Cell Metab) identified MOTS-c as a 16-aa mitochondrially-encoded peptide that increases insulin sensitivity in mouse models via AMPK activation, with reduced obesity and insulin resistance. The mechanism (folate-purine-AMPK pathway) has been confirmed across multiple labs. As of 2026, no human RCT of MOTS-c administration has been published.
1 human study · 8 animal studies
Key findings & citations
- Lee 2015: MOTS-c reduced obesity and insulin resistance in high-fat-fed mice.
- Mechanism: AMPK activation via folate-purine pathway.
- Endogenous MOTS-c levels track with metabolic health in humans (Ramanjaneya 2019).
- Zero human RCTs of MOTS-c administration.
Our take
Beautiful mechanism, zero administered human data. Community use is purely experimental.